New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 13, 2012
12:40 EDTBBY, CLWR, S, ZAGG, MBI, BAC, RIGL, AZN, ALLTOn The Fly: Midday Wrap
Stocks on Wall Street were lower at midday, extending the slide that began late yesterday following Ben Bernanke's press conference. House Speaker John Boehner and Senate Majority Leader Harry Reid both held press conferences within about the last hour, bringing the fiscal cliff fight back to the forefront of investors' minds... ECONOMIC EVENTS: In the U.S., weekly jobless claims fell 29,000 to 343,000, versus expectations for a drop to 369,000. Producer prices in the month of November fell 0.8%, versus an expected decline of 0.5%. "Core" prices, excluding food and energy, rose 0.1%, which matched expectations. Retail sales rose 0.3% in November, which missed expectations for an increase of 0.5%. In Europe, the region's finance ministers approved the long-delayed release of financial aid to Greece. Also, an agreement was reached on the foundation of a true banking union with ECB oversight... COMPANY NEWS: Best Buy (BBY) jumped over 15% after Minneapolis' Star Tribune said the company's founder Richard Schulze may make a fully financed $5B-$6B buyout offer by the end of the week... Clearwire (CLWR) rose nearly 14% to $3.13 after Sprint (S) disclosed that it offered $2.90 per share for the remaining stake in the company it does not already own. Clearwire said that its talks with Sprint are ongoing... MAJOR MOVERS: Among the notable gainers were ZAGG (ZAGG), up 15% after announcing a $10M share repurchase program, and MBI (MBIA), up 6.5% following positive analyst commentary about the potential for a settlement with Bank of America (BAC). Among the noteworthy losers was Rigel Pharmaceuticals (RIGL), which fell almost 35% after an RA drug it is developing in partnership with AstraZeneca (AZN) failed to meet one of its endpoints in a trial. Shares of AstraZeneca, meanwhile, fell 2.6%. Also lower were shares of Allot Communications (ALLT), down over 11% following a downgrade to Hold at Wunderlich... INDICES: Near 12:30 pm ET, the Dow was down 19.89, or 0.15%, to 13,225.56; the Nasdaq was down 21.52, or 0.71%, to 2,992.29; and the S&P 500 was down 7.47, or 0.52%, to 1,421.01.
News For BBY;CLWR;S;ZAGG;MBI;BAC;RIGL;AZN;ALLT From The Last 14 Days
Check below for free stories on BBY;CLWR;S;ZAGG;MBI;BAC;RIGL;AZN;ALLT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
August 18, 2014
06:47 EDTBACU.S. banks consider Ireland fitting spot for EU divisions, FT says
Subscribe for More Information
August 15, 2014
10:07 EDTBACBank of America reports July default rate 3.01% vs. 3.24% last month
Subscribe for More Information
10:01 EDTMBIOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:10 EDTMBIOn The Fly: Pre-market Movers
Subscribe for More Information
07:35 EDTMBIMBIA upgraded to Buy from Neutral at BTIG
Subscribe for More Information
06:15 EDTSSprint's new CEO to introduce 'disruptive' prices next week, Re/code reports
Subscribe for More Information
August 14, 2014
14:13 EDTSOmega Advisors gives quarterly update on stakes
Subscribe for More Information
12:01 EDTAZNThird Point gives quarterly update on stakes
NEW STAKES: Rackspace (RAX), Finisar (FNSR), Amgen (AMGN), Ally Financial (ALLY), and AstraZeneca (AZN). INCREASED STAKES: Dollar General (DG) and Dow Chemical (DOW). DECREASED STAKES: FedEx (FDX), Hertz (HTZ), T-Mobile (TMUS) and Intrexon (XON). LIQUIDATED STAKES: Google Class A (GOOGL), Verizon (VZ) and Mondelez (MDLZ).
09:07 EDTSMorgan Stanley to hold a conference
Subscribe for More Information
08:28 EDTBACBofA, DOJ still in talks over $17B settlement, NY Post says
Subscribe for More Information
August 13, 2014
09:15 EDTRIGLOn The Fly: Pre-market Movers
Subscribe for More Information
08:31 EDTAZNAstraZeneca says Phase 3 trials of lesinurad for gout met primary endpoints
AstraZeneca announced top-line results from CLEAR1, CLEAR2 and CRYSTAL, the pivotal Phase III clinical trials investigating the potential of lesinurad, a selective uric acid re-absorption inhibitor, as a combination therapy for the treatment of patients with symptomatic gout. Lesinurad is an investigational agent that inhibits the URAT1 transporter, increasing uric acid excretion and thereby lowering serum uric acid. In the CLEAR1 and CLEAR2 trials, both lesinurad 200mg and 400mg in combination with allopurinol met the primary endpoint, with a statistically significant higher proportion of patients reaching the target sUA goal of <6.0mg/dL at month 6 compared to allopurinol alone. In the CRYSTAL trial, lesinurad 400mg in combination with febuxostat met the primary endpoint, with a statistically significant higher proportion of patients reaching the target sUA goal of <5.0mg/dL at month 6 compared to febuxostat alone. Although lesinurad 200mg did not achieve statistical significance at month 6, this dose in combination with febuxostat, was superior to placebo plus febuxostat at all other time points. Results from these Phase III clinical trials will be submitted to a scientific meeting later in 2014. The company is proceeding with preparation of regulatory submissions for lesinurad 200mg combination therapy.
07:31 EDTRIGLRigel Pharmaceuticals announced R348 did not meet endpoints in Phase 2 study
Subscribe for More Information
August 12, 2014
17:26 EDTSDish viewed as favored T-Mobile acquirer after Sprint drops bid, Bloomberg says
Dish Network (DISH) is viewed as a favorite to acquire T-Mobile (TMUS) after Sprint (S) dropped its plans to acquire the company last week, according to Bloomberg, citing analysts at Moody's Investors Service and Macquarie Group. Being an industry outsider, Dish wouldn't reduce the number of competitors in the wireless market, which would please regulators, Bloomberg added. Reference Link
09:35 EDTBACActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL GOOG C TSL EXAS BAC DNDN JNJ TSLA
08:03 EDTBBYGoldman's Retail selections for Q2
Goldman is most above Q2 consensus for Advance Auto Parts (AAP), Best Buy (BBY) and Williams-Sonoma (WSM), sees best risk/reward in Ulta Salon (ULTA) and Sportsman's Warehouse (SPWH), and low visibility in Dick's Sporting (DKS) and Wal-Mart (WMT).
07:48 EDTBACBanks posted second-highest profit in 23 years in second quarter, WSJ says
Subscribe for More Information
05:58 EDTAZNStocks with implied volatility movement; P AZN
Subscribe for More Information
August 11, 2014
18:05 EDTSSprint CEO to utilize price cuts to 'compete aggressively', Bloomberg reports
Subscribe for More Information
06:01 EDTSStocks with implied volatility movement; S APC
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use